Background-Left ventricular remodeling, as commonly measured by left ventricular ejection fraction (LVEF), is associated with clinical outcomes. Although change in LVEF over time should reflect response to therapy and clinical course, serial measurement of LVEF is inconsistently performed in observational settings, and the incremental prognostic value of change in LVEF has not been well characterized. Methods and Results-The β-Blocker Evaluation of Survival Trial measured LVEF by radionuclide ventriculography at baseline and at 3 and 12 months after randomization. We built a series of multivariable models with 16 clinical parameters plus change in LVEF for predicting 4 major clinical end points, including the trial's primary end point of all-cause mortality. Among 2484 patients with at least 1 follow-up LVEF, change in LVEF was the second most significant predictor (behind baseline creatinine) of all-cause mortality (adjusted hazard ratio for improvement in LVEF by ≥5 U responder versus nonresponder [95% confidence intervals] for all-cause mortality=0.62 [0.52-0.73]). Other end points, including heart failure hospitalization or the composite of all-cause mortality and heart failure hospitalization, yielded similar results. LVEF change ≥5 U was associated with a modest increase in discrimination when added to traditional predictors and was predictive of outcomes in both the bucindolol and placebo treatment groups. LVEF change as a predictor of outcomes was affected by sex and race, with evidence that LVEF improvement is associated with less survival benefit in African Americans and women. Conclusions-Serial evaluation for LVEF change predicts both survival and heart failure hospitalization and provides a dynamic/real-time measure of prognosis in heart failure with reduced LVEF. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000560.
L eft ventricular ejection fraction (LVEF) is an important predictor of mortality in patients with heart failure (HF) and is used to define many drug and device therapeutic indications. [1] [2] [3] [4] [5] [6] [7] [8] Improvement in LV remodeling by neurohormonal inhibitor pharmacological therapy or cardiac resynchronization therapy is associated with improved survival and reduced HF hospitalizations. 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Clinical practice guidelines recommend repeat measurement of LVEF when there is a clinical change or need to assess response to therapy. 1 Understanding the clinical implications of serial changes in LVEF may help guide the frequency of measurement, anticipate individual patient responses to evidence-based therapy, and augment existing risk model calculators.
See Clinical Perspective
Despite the apparent importance of changes in LVEF, limited data exist on the link to clinical outcomes. A small (n=160) substudy of the Cardiac Insufficiency Bisoprolol Study revealed that serial improvement in left ventricular fractional shortening was associated with improved survival. 19 A small (n=141) device study has shown that incremental LV systolic volume changes of 10% are associated with survival and HF hospitalization. 20 Although these studies support that serial LV measurements have predictive prognostic value, none of them have been performed in a large patient cohort with an extensive number of clinical events, featured a systematic approach Outcomes With Left Ventricular Remodeling to timing of LVEF measurements, used a consistent method of LVEF assessment, or investigated changes in LVEF by race or sex. 13, [20] [21] [22] [23] We, therefore, set out to characterize changes in LVEF and their association with clinical outcomes in BEST (β-Blocker Evaluation in Survival Trial). BEST included 2708 racially diverse patients with advanced (New York Heart Association class III or IV) HF in whom LVEF measurements were obtained at regular intervals by a single modality, radionuclide ventriculograms (RVGs), that included core laboratory oversight and adjudication of cause of mortality cause by an independent clinical events committee. On the basis of the degree of RVG LVEF change that is accompanied by favorable molecular phenotypic changes, 24, 25 we hypothesized that improvement in LVEF and specifically an increase by ≥5 U would be a strong predictor of reduction in major HF clinical end points.
Methods
The design and primary findings of BEST have been published previously. 26, 27 Briefly, BEST was a randomized, placebo-controlled phase 3 mortality trial conducted between 1995 and 1999 to test the efficacy of bucindolol for preventing all-cause mortality (ACM) in patients with advanced HF with reduced ejection fraction (HFrEF). Eligible patients were 18 years or older with LVEF ≤35%, New York Heart Association functional class III or IV secondary to ischemic or nonischemic HF. 26 All patients were on optimal medical therapy (as defined at that time) for at least 1 month before enrollment, which included an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker if angiotensin-converting enzyme inhibitor intolerant, diuretics as needed, and during the first 2 years of the trial digoxin (until contemporary literature led to a change in the indication to optional). 26 Ninety-two percent of patients were receiving an angiotensin-converting enzyme inhibitor with an additional 6% receiving an angiotensin receptor blocker; 92% were receiving digoxin; and 94% were receiving diuretics. Inclusion/exclusion criteria were typical for an HFrEF trial. 26 Patients were followed for a mean of 2 years, with regular study visits at 3, 6, 12 months, and then every 6 months. Written informed consent was obtained for each patient at each clinical site in the BEST, as previously described. 26 
Sample Size
The BEST randomized 2708 patients, which defines the entire cohort. Baseline and 3-month RVGs were completed in 2460 patients, whereas a total of 2034 patients had baseline and 12-month RVGs. Missing 12-month LVEF values (n=450) were imputed from 3-month values, including the 228 patients who died between 3 and 12 months. Thus, patients had to have LVEF not available at both the 3-and 12-month visits to be excluded from the analysis (Figure 1 ). Reasons for patients' exclusion were (1) 85 deaths before the 3-month visit;
(2) 58 nonfatal adverse effects leading to study withdrawal; (3) 40 withdrawals for personal/administrative reasons; (4) 4 cardiac transplants; and (5) 37 for missed follow-up visits or other reasons. The final study population was 2484 patients, 1226 in the bucindolol group and 1258 in the placebo group, constituting the LVEF analysis cohort.
LVEF Measures
Serial LVEF measures were a secondary end point in BEST. The patients underwent RVG within the 60 days before randomization, with repeat RVG at 3-(92±8.8 days) and 12-month (366±17.3 days) post randomization. 26 LVEF data were calculated by site personnel using commercially available analytic methods and software. Quality control oversight of the RVG methodology was provided by the trial and performed in the Cardiac Imaging Core Laboratory at Tufts Medical Center in Boston, MA, on the first 2 studies at each site and ≈5% of the studies thereafter. On the 3 quality assurance rounds, 73% to 76% of the studies were assessed as good quality, and 67% to 76% were reported as having no technical problems. Analysis of the remaining RVGs, that is, those of fair or poor quality or having a technical problem, was repeated. LVEF values, including changes from baseline, are given as mean±SD.
Outcomes
The outcomes of interest for this study were time to first event of ACM, the primary end point of BEST, cardiovascular mortality (CVM), HF hospitalization, and ACM or HF hospitalization assessed in the total LVEF analysis cohort irrespective of treatment group. HF hospitalization was identified by study investigators on hospitalization case report forms. A post hoc adjudication by the independent end points committee 28 revealed similar classification of HF hospitalization events.
Predictors
To assess the independent association of changes in LVEF with outcomes, Cox proportional hazards regression models were constructed for each end point from a set of eligible predictors in stepwise fashion. The set of eligible HF predictors was selected based on characteristics that could potentially affect the study hypothesis (LVEF change), subgroups predefined in the BEST protocol (presence or absence of coronary artery disease, sex, race, age [ 26, 29, 30 ) , and additional predictors that have been associated with HF outcomes (volume overload at baseline, HF duration [months/25], and presence of diabetes mellitus). 2, 3 The predefined subgroup variable of baseline norepinephrine was not included in the model because of a large number of missing values. 31
Statistical Analysis
Cox models were initially constructed using continuous LVEF change data (change at 12 months with last observation carried forward from 3 months), and the various baseline input variables were rank ordered by significance level. Once the models were constructed for each end point, the continuous change in LVEF predictor was replaced with an indicator of LVEF responder (absolute change in LVEF from baseline to 12 months ≥5 U, with last observation carried forward from 3 months) versus nonresponder (all others) to calculate hazard ratios (HRs) to quantify the impact of LVEF responder/nonresponder versus other variables. Baseline patient characteristics for the total study population and the LVEF analysis cohort were analyzed with descriptive statistics. In the stepwise model, new baseline predictors were added for a significance level of 0.25, and predictors were retained for a significance level of 0.20. C-index was calculated for the models with and without the LVEF responder term.
Supportive secondary analyses were also performed using a Landmark approach 32 and a time-dependent covariate approach. 33 Because LVEF was assessed at baseline and at 3 and 12 months, a natural study interval was created for Landmark analysis at 12 months. This analysis excluded all patients missing 3-or 12-month LVEF measurements (n=450), which left 2034 patients available for assessment of end points starting at the 12-month visit. Baseline predictors were applied to the models as above.
The time-dependent covariate approach used change from baseline LVEF at the time of each event. In this approach, a full study (n=2708) data set was constructed with estimated 3-and 12-month values, which were derived via interpolation for subjects with postbaseline LVEF data. LVEF values at 3 and 12 months were imputed, and interpolation was then used to estimate LVEF at times of events occurring before the actual or imputed 12-month visit. For events after this visit, LVEF was estimated via last observation carried forward of the actual or imputed 12-month value. This approach described in more detail in the Data Supplement enabled all observed study deaths and hospitalization events to be included in the models.
Additional secondary analyses stratifying by self-identified race (African American, self-identified versus non-African American) and sex for each outcome were also performed using the model with an input of LVEF responder/nonresponder. Statistical analyses were performed using SAS 9.3 (Cary, NC), and the significance level was set at 0.05 for all tests.
Results
In the LVEF analysis cohort of 2484 patients, the mean±SD baseline LVEF was 23.1±7.3%. The average age was 60 years; 78% were men; 22% were African American; 58% had ischemic etiology; and 92% were New York Heart Association functional class III (Table 1) . When patients were subdivided into responders (LVEF improvement ≥5 U) or nonresponders (all others), there were more responders in the bucindolol treatment group versus placebo group (52% versus 33%, P<0.0001). All clinical events occurred more commonly in patients who did not have ≥5 U LVEF improvement (nonresponders, Table 3 ; Figure 2C ). A ≥5 U LVEF improvement (responder status) was associated with significant risk reduction in all clinical end points, following adjustment and regardless of treatment group. The predictors chosen for the Cox model for each end point appear in Figure 3A through 3D in the order in which they were statistically selected. For ACM, LVEF responders/nonresponders had an HR (95% confidence intervals) of 0.62 (0.52-0.73) in the total LVEF analysis cohort ( Figure 3A) , 0.59 (0.47-0.74) in the bucindolol-treated subgroup ( Figure 4A ), and 0.65 (0.52-0.82) in the placebo-treated subgroup (interaction P=0.58, Figure 4A ). For CVM, the responders/nonresponders HR was 0.54 (0.45-0.65) in the total LVEF analysis cohort ( Figure 3B ), 0.53 (0.41-0.68) in the bucindolol subgroup ( Figure 4A ), and 0.55 (0.43-0.72) in the placebo subgroup (interaction P=0.90, Figure 4A ). For HF hospitalization, responders/nonresponders had an HR of 0.66 (0.57-0.76) in the total LVEF analysis cohort ( Figure 3C ), 0.69 (0.56-0.84) in the bucindolol subgroup ( Figure 4A ), and 0.64 (0.53-0.78) in the placebo subgroup (interaction P=0.78, Figure 4A ). For ACM or HF hospitalization, the responders/nonresponders had an HR of 0.67 (0.59-0.76; Figure 3D ) in the total LVEF analysis cohort, 0.67 (0.56-0.79) in the bucindolol subgroup ( Figure 4A ), and 0.68 (0.58-0.81) in the placebo subgroup (interaction P=0.57, Figure 4A ). Of all clinical predictors, LVEF change and serum creatinine demonstrated the most consistent relationship to the risk of ACM, CVM, HF hospitalization, and ACM or HF hospitalization. LVEF responder ≥5 U resulted in a modest increase in C-index when added to the models with the other selected predictors compared with traditional predictor models (Table 3; Figure 4 ). In addition, the risk for ACM declines with greater serial change in LVEF (Table 4) .
These results were confirmed using a Landmark analysis approach (Table 3) . For ACM, responders/nonresponders had an HR of 0.64 (0.52-0.78) compared with 0.62 (0.52-0.73) for the original approach. Thus, the predictive power of the LVEF response indicator was maintained with the reduced event set.
The results were also confirmed with the models that used a time-dependent covariate for LVEF (Table 3 ). These models included an additional 154 deaths and 104 HF hospitalizations that were omitted from the original approach because of missing values of LVEF and other covariates. For ACM, responders/nonresponders had an HR of 0.77 (0.66-0.89) compared with 0.62 (0.52-0.73) for the original approach. For HF hospitalization, responders/nonresponders had an HR of 0.66 (0.56-0.78) compared with 0.66 (0.57-0.76) with the original approach. By race, the responder mortality rate was 44% (244/559) in African Americans and 42% (807/1925) in non-African Americans (P=0.47). The ability to predict risk by ≥5 U LVEF change was similar in African Americans and non-African Americans for HF hospitalization, but not for mortality end points ( Figure 4B ). For ACM and CVM, responder versus nonresponder status in African Americans yielded nonsignificant HRs of, respectively, 0.75 (0.54-1.05) and 0.70 (0.48-1.02), with interaction test P values of 0.08 and <0.05 compared with non-African Americans who had HRs of 0.57 (0.47-0.69) for ACM and 0.50 (0.40-0.61) for CVM. In contrast, the responder/ nonresponder HF hospitalization HR was significant for African Americans, 0.76 (0.58-0.99), and closer to the non-African Americans HR of 0.63 (0.54-0.75), with a nonsignificant test for interaction (P=0.20). The composite end point of ACM/HF hospitalization, driven by HF hospitalization rates, also had a nonsignificant interaction test (P=0.11) between races.
By sex, the responder ACM rate was 44% (232/533) in women and 42% (819/1951) in men (P=0.52). For sex ( Figure 4C ) and ACM or CVM end points, responder/nonresponder status yielded nonsignificant HRs in women and statistically significant, lower HRs in men, with nonsignificant tests for interaction. In contrast, there were no differences between sexes for HF hospitalization or ACM/HF hospitalization, with both women and men exhibiting statistically significant HRs in the 0.66 to 0.67 range and nonsignificant tests for interaction.
Discussion
Improvement in LVEF by ≥5 U was a powerful predictor of survival and reduced HF hospitalization, rivaling baseline serum creatinine in predictive value. Importantly, LVEF serial improvement was just as positively predictive in the placebo group as in β-blocker-treated patients with an as expected higher percentage of LVEF improved patients in the bucindolol group. These data provide important information on the meaning of change in LVEF in patients with HFrEF. With HF being one of the leading causes of death and rehospitalization The total number of patients was 2484. Number (%) is presented for all variables. HR with 95% confidence intervals is shown. ACM indicates all-cause mortality; CVM, cardiovascular mortality; HF, heart failure; HR, hazard ratio; and LVEF, left ventricular ejection fraction.
*The rate of response/nonresponse among total patients. †The rate of events among the responders or nonresponders. The baseline values of the following 16 standard heart failure predictors were eligible to be included in each model in a stepwise fashion: active atrial fibrillation on enrollment, age, CAD, creatinine, diabetes mellitus, duration of HF, fluid overload on enrollment, heart rate, LVEF baseline (stratified by ≤20% and >20%), New York Heart Association class, race, sex, site type, sodium, study treatment group, and systolic blood pressure. In addition, the change from baseline to the 12-mo visit in LVEF (with replacement of missing values with the 3-mo result) was included as an eligible predictor. Once the models were constructed for each end point, the continuous change in LVEF predictor was replaced with an indicator of LVEF responder (change in LVEF from baseline to month 12 ≥5 U) vs nonresponder (change in LVEF from baseline to month 12 <5 U) to calculate HRs to quantify the impact of LVEF response of this magnitude. C-index was calculated for the models with and without the LVEF ≥5 U change term, and all were found to be significant at P<0.001. The event counts increase in the time-dependent covariate approach because all study patients are included compared with patients without LVEF at 3 and 12 mo being omitted in the original approach. Outcomes With Left Ventricular Remodeling in the United States, this information is relevant to healthcare delivery 1,2 inasmuch as change in LVEF provides a dynamic, real-time measure of a patient's major clinical outcomes risk based on the medical management that is being delivered. Serum creatinine or other risk stratifying static variables measured in this study may provide useful information on prognosis but do not provide ongoing information relevant to therapeutic management. Other dynamic measures, such as change in B-type natriuretic peptide markers or systemic norepinephrine, could also provide such information but were not evaluated in the LVEF analysis cohort trial and in addition may have anomalous effects in bucindolol 31, 34 and other β-blocker-treated patients. 35, 36 Despite the limitations of previous investigations of serial changes in LVEF in patients with HFrEF, the potential clinical value of such observations has been generally accepted. Repeat LVEF assessment is typically performed per guidelines to assess clinical change and response to β-blocker or cardiac resynchronization therapy but not in a systematic fashion for prognostic assessment in the outpatient setting. 1, 37 Multiple validated risk models, including the Seattle Heart Failure Model, Heart Failure Survival Score, Meta-Analysis Global Group in Chronic Heart Failure Model, and Controlled Rosuvastatin Multinational Trial in Heart Failure Risk Score, all have moderate ability to predict mortality but have poor ability to predict risk of HF hospitalization in the ambulatory HF patient. [3] [4] [5] [6] Each of these models includes LVEF but not serial changes in LVEF. Considering that the current analysis and other smaller studies have consistently shown that serial LVEF change is associated with survival, and our data indicate superiority to a single baseline measure, serial LVEF change may provide some incremental predictive performance for the existing models. 9, 13, [20] [21] [22] [23] 38 Several studies have shown that serial LVEF change ≥10 U is associated with mortality, but the lack of standardized methods or small patient population has limited their applicability. 13, [20] [21] [22] [23] A recent study by Zhang et al 23 showed that a longitudinal 5 U LVEF change had an impact on mortality in patients with HFrEF eligible for implantable cardioverter defibrillator. The BEST had the advantage of routine assessment of LVEF at baseline and at 3-and 12-month intervals in a large patient population, rather than being performed as clinically indicated in a registry. Furthermore, the use of RVG and a Cardiac Imaging Core Laboratory providing quality assurance improves the discriminatory ability to identify LVEF and follow longitudinally for change. 39 This provides the power to strongly associate change in LVEF ≥5 U with outcomes of survival and HF hospitalization.
We provide the first evidence that race or sex may affect the clinical predictive characteristics of LVEF serial change, with outcomes appearing to differ for mortality versus HF hospitalization-driven end points. In contrast to non-African Americans, in African Americans, LVEF responder status was not predictive for ACM or CVM but was for HF hospitalization. The race finding for CVM was meaningful and is supported by a test for interaction (P<0.05) of the endpoint and race. This is an important finding that adds to epidemiological and registry studies that have shown that the magnitude of LVEF change may vary by race and sex, with lower LVEF changes in African American men compared with white men and women. 38, 40, 41 Our data indicate that even when LVEF improves in African American, there may be less of a mitigating effect on survival compared with non-African American. As a post hoc analysis, this finding should be considered hypothesis generating because racial differences in the clinical response to LVEF change could be secondary to differences in baseline characteristics between African Americans and non-African Americans 42 that were not completely adjusted by Cox modeling. However, these findings could also be because of racial genetic differences that influence the response to neurohormonal inhibitors. 43 To date, the BEST contains one of the largest populations of African American patients, representing 23% of the entire cohort and 22% of the LVEF analysis cohort, but may be underpowered to assess the full benefit of LVEF change by race. The ability to calculate risk in the African American population is vital because they may have the greatest benefit given their higher risk for the development and severity of HF. 2, 40 Further study in African-Americans is indicated.
Sex also appeared to be associated with a differential effect of LVEF change, with higher and nonsignificant HRs in women versus men for mortality end points, but no difference for HF hospitalization-driven end points. The data supporting a sex-related difference of LVEF change for mortality end points were not as strong as for race, with nonsignificant tests for interaction. Because of the large contribution of Veterans' Administration Hospitals as study sites, women were underrepresented (22% of total) in BEST, and as for race the impact of β-blocker-associated reverse remodeling by sex needs further investigation.
Study Limitations
We relied on RVG for LVEF assessment, which delivers reliable data that are consistent across centers but can be impractical given radiation exposure and cost. Although 5 U change in LVEF has less interobserver variability by RVG than echocardiogram, intraobserver variability has been <5% for echocardiogram and may make serial sonographic measures of LVEF similarly relevant. 39, 44 This study was performed before standard use of the guidelineapproved therapies aldosterone antagonists, β-blockers, and cardiac resynchronization therapy devices. However, The predictors included the presence vs absence of disease in binary fashion unless noted otherwise: age (continuous: y/10); atrial fibrillation; coronary artery disease (CAD); congestive heart failure (CHF) duration (continuous variable in mo/25); creatinine (continuous: mg/dL); diabetes mellitus; baseline left ventricular ejection fraction (LVEF) <20% vs ≥20%; fluid overload; heart rate (continuous: beats per minute/10); LVEF responder, change in LVEF from baseline to month 12 ≥5 U; New York Heart Association (NYHA) class III vs IV; race, African Americans vs non-African Americans; systolic blood pressure (SBP; continuous: mm Hg/10); sex, males vs females; site type, veteran affairs medical center vs nonveteran affairs medical center; sodium (continuous: mEq/L/5); and treatment, treatment group bucindolol vs placebo. χ 2 P indicates the χ 2 P value. Outcomes With Left Ventricular Remodeling contemporaneous studies assessing the value of serial LVEF change have shown findings consistent with this study. 9, 23 Responder outcome studies have been associated with bias in the absence of Landmark analyses 32 ; however, in this study, Landmark analyses produced similar results to those found with main study methodology. Landmark analyses include risks of misclassification, omitting events, and datadriven results but can be avoided by sensitivity analysis and time-dependent analysis. 32 The additional time-dependent covariate approach performed in this study remained supportive of the initial analyses. This was a highly selected trial population with a mean age of 60 years, and thus the findings reported here may not have external validity when applied to large, real-world settings; however, measures of risk tend to have even better discrimination when applied to more homogeneous populations of patients.
Conclusions
In the BEST study, we found that ≥5 U LVEF change powerfully predicts risk of ACM, CVM, and HF hospitalization in HFrEF. Serial LVEF was performed routinely by a single method in a large diverse patient population and had no deviations in predictability of outcome across treatment groups with the exception of ACM and CVM for African Americans and women. Further validation of the incremental prognostic value of change in LVEF for important clinical decisions across various populations with HF is needed. 
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